Learn about transaminitis secondary to rosuvastatin, including diagnosis, clinical documentation, and medical coding. Find information on elevated liver enzymes, drug-induced liver injury, rosuvastatin side effects, and ICD-10 codes for transaminitis and statin-induced liver damage. This resource helps healthcare professionals accurately document and code transaminitis related to rosuvastatin use. Explore the relationship between rosuvastatin therapy and liver function tests (LFTs) abnormalities, and find guidance on appropriate management and coding best practices.
Also known as
Other diseases of liver
This code captures unspecified liver diseases, encompassing drug-induced liver injury.
Adverse effect of statins
This code specifically identifies adverse reactions caused by statin medications like rosuvastatin.
Unspecified jaundice
Elevated transaminases can sometimes lead to jaundice, and this code captures such cases.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is the transaminitis definitively caused by rosuvastatin?
Yes
ALT/AST levels documented?
No
Is another cause more likely?
When to use each related code
| Description |
|---|
| Rosuvastatin-induced transaminitis |
| Drug-induced liver injury (DILI) |
| Non-alcoholic fatty liver disease (NAFLD) |
Rosuvastatin-induced transaminitis requires proper sequencing (T26.81XA, E78.2) to demonstrate causality. Miscoding can lead to inaccurate reporting.
Coding transaminitis without specifying the drug (rosuvastatin) lacks detail for accurate severity and compliance tracking (use T26.81XA).
Insufficient documentation of abnormal liver function tests (e.g., ALT, AST) supporting transaminitis can lead to claim denials.
Patient presents with elevated liver enzymes, consistent with a diagnosis of transaminitis secondary to rosuvastatin use. The patient reports taking rosuvastatin, a statin medication prescribed for hyperlipidemia and cholesterol management. Current symptoms include (but are not limited to) fatigue, nausea, and right upper quadrant abdominal discomfort. Onset of symptoms occurred approximately [timeframe] after initiating or increasing the dosage of rosuvastatin. Physical examination revealed [relevant findings, e.g., mild right upper quadrant tenderness, no hepatomegaly or jaundice]. Laboratory results demonstrate elevated alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, exceeding the upper limit of normal by [number] times. Other liver function tests, including alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), and bilirubin, are within normal limits or only mildly elevated. Differential diagnoses considered include non-alcoholic fatty liver disease (NAFLD), viral hepatitis, and drug-induced liver injury (DILI). Given the temporal relationship between rosuvastatin initiation and the onset of symptoms and laboratory abnormalities, rosuvastatin-induced transaminitis is the most likely diagnosis. Rosuvastatin will be discontinued and replaced with an alternative lipid-lowering agent, such as [alternative medication, e.g., ezetimibe, fenofibrate, or a PCSK9 inhibitor]. Patient education provided regarding the potential hepatotoxicity of statins and the importance of medication adherence and follow-up. Repeat liver function tests will be performed in [timeframe] to monitor for resolution of transaminitis. The patient is advised to return for evaluation if symptoms worsen or new symptoms develop. ICD-10 code: T46.5X5A (Adverse effect of statins).